Table 3. Bivariate subgroup analysis of patients with high or low BSI lesions combined with either Bcl-2−/+ or p53−/+ or MSI−/+ samples in relation to 5-year DFS and 5-year OS (log-rank test).
| n | 5-year DFS (%) | P | 5-year OS (%) | P | |
|---|---|---|---|---|---|
| BSI high/Bcl-2− | 24 | 82.6 | 0.2 | 87.1 | 0.2 |
| BSI high/Bcl-2+ | 87 | 68.8 | 73.1 | ||
| BSI low/Bcl-2− | 33 | 56.8 | 0.7 | 59.5 | 0.7 |
| BSI low/Bcl-2+ | 44 | 41.4 | 61.4 | ||
| BSI high/p53− | 58 | 80.7 | 0.03 | 80.8 | 0.07 |
| BSI high/p53+ | 53 | 61.9 | 70.9 | ||
| BSI low/p53− | 36 | 45.5 | 0.7 | 58.5 | 0.8 |
| BSI low/p53+ | 41 | 50.4 | 62.6 | ||
| BSI high/MSI− | 97 | 68.6 | 0.11 | 73.7 | 0.13 |
| BSI high/MSI+ | 7 | 100 | 100 | ||
| BSI low/MSI− | 61 | 44.4 | 1 | 58.6 | 0.9 |
| BSI low/MSI+ | 9 | 55.6 | 66.7 |
BSI=BAX staining index; DFS=disease-free survival; 5-FU=5-fluorouracil; LEV=levamisole; MSI=microsatellite instability; OS=overall survival. Bold values signify P<0.05.